Valacyclovir Trial Drives Increased CMV Screening in Pregnancy
A 2020 valacyclovir trial significantly reduced congenital cytomegalovirus (CMV) transmission, leading to a substantial increase in CMV screening and valacyclovir use in pregnant women in France. This shift in practice did not raise termination of pregnancy rates, offering a crucial advancement in preventing this leading cause of neurosensory impairment.
Key Highlights
- CMV screening and valacyclovir use rose in France after a 2020 trial.
- The 2020 trial showed valacyclovir cut vertical CMV transmission by two-thirds.
- Increased screening was not linked to a rise in pregnancy terminations.
- European expert groups have since recommended valacyclovir for early pregnancy infections.
- Congenital CMV is the leading infectious cause of neurosensory impairment globally.
- The findings hold significant implications for global maternal-fetal health strategies, including in India.
Cytomegalovirus (CMV) screening and the use of the antiviral drug valacyclovir during pregnancy have seen a substantial increase in France. This surge in medical practice followed the publication of a pivotal randomized controlled trial in 2020, which demonstrated the efficacy of valacyclovir in preventing the vertical transmission of CMV from mother to fetus. The European Medical Journal (EMJ) reported that this shift in antenatal care has not been accompanied by an increase in termination of pregnancy rates, addressing a long-standing concern regarding broader screening policies.
The 2020 trial, led by Shahar-Nissan et al., was a prospective, randomized, double-blind, placebo-controlled study conducted in Israel. It investigated whether valacyclovir could prevent vertical transmission of CMV in pregnant women with primary infection acquired early in pregnancy. The findings were significant: the valacyclovir group experienced a notably lower rate of CMV-positive amniocenteses (11%) compared to the placebo group (30%), indicating a 71% relative reduction in transmission risk, approximately two-thirds. This evidence of efficacy has been further supported by other studies and a 2023 meta-analysis, solidifying valacyclovir's role in secondary prevention of congenital CMV.
Congenital CMV infection is a critical global health concern, recognized as the leading infectious cause of congenital neurosensory impairment worldwide. In France, approximately 0.4% of newborns are affected by congenital CMV, which can lead to severe outcomes such as psychomotor delay or sensorineural hearing loss, particularly if maternal infection occurs in the first trimester. Following the influential 2020 trial, systematic CMV screening in France dramatically increased from 22.0% between 2017 and 2020 to 40.0% between 2021 and 2023. Maternal requests for testing also rose from 0% to 4.2% during the same periods. Consequently, the use of antiviral therapy, predominantly valacyclovir, climbed from 27.7% before 2021 to 59.8% afterwards.
The implications of these findings extend beyond France. European expert groups have subsequently recommended valacyclovir for women infected during the periconceptional period or early pregnancy. The effectiveness of valacyclovir in reducing vertical transmission has prompted discussions about universal prenatal screening for CMV in other regions, including the United States, where it is not yet routinely recommended despite growing evidence of valacyclovir's benefits. Studies are also exploring the cost-effectiveness of universal screening and valacyclovir prophylaxis, with some analyses suggesting it could be a cost-saving intervention by preventing costly sequelae in children.
For India, this news carries significant relevance. Cytomegalovirus is highly prevalent in the Indian population, with studies indicating that 80-90% of individuals carry the virus asymptomatically due to inherent immunity. However, CMV poses a serious threat to immunocompromised individuals, including transplant recipients and HIV-infected persons. Critically, India witnessed sporadic cases of CMV complications, such as gastrointestinal bleeding and pneumonia, in COVID-19 recovered patients, particularly those who received high doses of steroids, which suppress the immune system. This highlights the vulnerability of a large segment of the Indian population to symptomatic CMV infection when immunity is compromised. Furthermore, congenital CMV is an under-investigated major health problem in India, necessitating strong preventive measures. The advancements in screening and prophylactic treatment with valacyclovir, as demonstrated by the European experience, offer a crucial pathway for India to develop more robust public health strategies to diagnose, prevent, and manage CMV infections, thereby reducing severe morbidity and mortality, especially in newborns and immunocompromised patients.
The European Medical Journal, the source of this article, is a reputable, peer-reviewed, open-access journal dedicated to advancing learning and research in medical sciences globally. Its editorial processes, including double-blind peer review and guidance from an expert editorial board, ensure the high quality and credibility of its published content. The news highlights a critical development in infectious disease management, reinforcing the importance of scientific research in shaping clinical guidelines and improving patient outcomes worldwide.
Frequently Asked Questions
What is Cytomegalovirus (CMV) and why is it a concern during pregnancy?
Cytomegalovirus (CMV) is a common herpes virus that often causes asymptomatic infection in healthy individuals. However, if a pregnant woman contracts a primary CMV infection, especially in the first trimester, the virus can be transmitted to the fetus (vertical transmission), leading to congenital CMV. This can cause severe health problems in newborns, including sensorineural hearing loss, developmental delays, and other neurosensory impairments.
How has the valacyclovir trial impacted CMV screening and treatment?
A pivotal randomized controlled trial in 2020 demonstrated that valacyclovir can significantly reduce the rate of vertical CMV transmission from mother to fetus by approximately two-thirds. This evidence has led to a substantial increase in CMV screening among pregnant women and a rise in the use of valacyclovir as a preventive treatment in countries like France, and has spurred recommendations from European expert groups.
Is routine CMV screening recommended globally or in India?
While the efficacy of valacyclovir has renewed interest in universal screening, routine prenatal CMV screening is not yet universally recommended in all countries, including the United States. In India, CMV is highly prevalent, and while it's a significant health concern for immunocompromised individuals and congenitally infected newborns, adequate investigations into diagnostic modalities and widespread screening are still needed.
What are the benefits of increased CMV screening and valacyclovir treatment?
Increased CMV screening allows for earlier detection of maternal infection, enabling timely intervention. Valacyclovir treatment, when administered to pregnant women with primary CMV infection, reduces the risk of vertical transmission, thereby preventing congenital CMV and its associated severe health sequelae in newborns. This approach aims to improve long-term outcomes for affected infants.
Why is this development particularly relevant for India?
CMV is endemic in India, with a high seroprevalence. It is a known cause of morbidity in immunocompromised patients and congenitally infected newborns. The emergence of CMV complications in post-COVID-19 patients further highlights India's vulnerability. Effective screening and prophylactic treatments, as demonstrated by the valacyclovir trial, offer crucial strategies for India to enhance its public health response to CMV, protect its vulnerable populations, and reduce the burden of congenital infections.
